Switzerland's Anergis Closes Series A Funding For Allergy Vaccine Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Anergis raises CHF 18 million from European venture funds to support Phase II study of fast-acting approach to allergy desensitization.
You may also be interested in...
Switzerland's Shield Therapeutics Raises $12M To Conduct Phase III Trials On Oral Iron Deficiency Product
Oral iron deficiency therapy to advance into Phase III this year on the back of $12 million fund raising for Swiss minnow, Shield Therapeutics.
Switzerland's Shield Therapeutics Raises $12M To Conduct Phase III Trials On Oral Iron Deficiency Product
Oral iron deficiency therapy to advance into Phase III this year on the back of $12 million fund raising for Swiss minnow, Shield Therapeutics.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2011
Biopharma companies raised $3.6 billion in Q1, with almost two-thirds coming from debt sales or follow-on public offerings. Seven of the 19 finalized mergers topped $500 million, but the biggest news was Valeant's attempt to takeover Cephalon. Lilly and BI signed the biggest deal of the quarter when they pooled their diabetes assets in an alliance worth $2.4 billion.